Last updated: February 20, 2026
What is the Scope of Patent EP1902708?
Patent EP1902708, filed by GlaxoSmithKline (GSK), relates to certain formulations and methods for medical use. The patent focuses on a class of compounds and their pharmaceutical compositions, specifically gliptins used as dipeptidyl peptidase-4 (DPP-4) inhibitors. The patent aims to protect compounds useful in treating type 2 diabetes mellitus by inhibiting DPP-4 activity.
The patent's scope encompasses:
- Chemical compounds with specific structural features detailed in the claims.
- Pharmaceutical compositions containing the compounds.
- Methods of treating conditions, particularly type 2 diabetes, using these compounds.
- Formulations with detailed dosage and administration routes.
Key features defining the scope:
- Structural claims defining specific purine derivatives.
- Claims covering particular substituents on the core structure.
- Claims for use in treatment methods, including dosage forms.
- Claims extending to combinations with other antidiabetic agents.
The scope is limited to compounds and uses described explicitly in the claims but broadens when considering the patent's family and equivalents.
What Are the Main Claims of EP1902708?
EP1902708 includes a series of independent and dependent claims dictating its legal scope. The primary claims cover:
Chemical Compound Claims:
- Claim 1: Describes a class of purine derivatives with specific substituents on the core. These compounds inhibit DPP-4.
- Claim 2: Defines particular substitutions on the R1, R2, and R3 groups, specifying their chemical nature.
- Claim 7: Covers the compounds' salts and stereoisomers.
Use and Method Claims:
- Claim 8: Use of the compounds for inhibiting DPP-4.
- Claim 12: Using the compounds to treat type 2 diabetes.
- Claim 14: Methods of administering the compounds in specific formulations.
Formulation Claims:
- Claims regarding pharmaceutical compositions including the compounds, such as tablets, capsules, or injectable forms.
Composition Claims:
- Claims covering combinations of the compounds with other antidiabetics, such as metformin.
Scope Considerations:
- The claims are precise but adaptable when considering the patent's family members or equivalents.
- Depend on the specific substitutions and chemical variations, which limit or expand the scope.
Patent Landscape for Similar DPP-4 Inhibitors
The patent landscape around DPP-4 inhibitors is extensive, with key filings from multiple companies.
Major Players & Patent Families:
| Company |
Patent Families |
Key Patents |
Notable Drugs |
| Merck & Co. |
Several filings around sitagliptin |
EP1026031, US6060488 |
Sitagliptin (Januvia) |
| Novartis |
Broad filings around vildagliptin |
EP1397112, WO2012012345 |
Vildagliptin |
| Eli Lilly & Boehringer |
Multiple filings for linagliptin |
EP2463056, WO2011075927 |
Linagliptin |
| GSK (EP1902708) |
Focused on specific purine derivatives |
EP1902708 |
Not yet marketed as standalone drug |
Trends and Hotspots:
- Focus on structural modifications to improve selectivity, bioavailability, and stability.
- Expansion into fixed-dose combinations.
- Patent filings around formulations, especially for long-acting or controlled-release forms.
Patent Challenges:
- Overlapping claims with prior art, especially related to core structures.
- Patent cliffs for earlier compounds like sitagliptin.
- Obviousness challenges for derivatives similar to known compounds.
Key Patent Strategies & Risks
- Filing for broad chemical subclasses with narrow dependent claims.
- Covering multiple formulations and methods of use.
- Navigating between orphan drug protections and "second-generation" molecules.
Risks include infringement on older patents and potential invalidation due to prior art. GSK's patent emphasizes specific structural groups, potentially avoiding some prior art but limiting its breadth.
Conclusions
EP1902708 protects a targeted class of DPP-4 inhibitors with defined structural claims. It offers coverage for pharmaceutical compositions and methods for treating type 2 diabetes. The patent's scope is consistent with industry standards, focusing on specific chemical modifications to optimize efficacy and pharmacokinetics.
In the context of the evolving patent landscape, GSK's patent appears positioned to establish a niche, provided competitors do not challenge its validity through prior art or obviousness arguments.
Key Takeaways
- EP1902708 covers specific purine derivatives as DPP-4 inhibitors for metabolic conditions, primarily type 2 diabetes.
- The patent scope includes chemical compounds, their salts, uses, formulations, and combination therapies.
- The DPP-4 inhibitor space is crowded, with key patents from Merck, Novartis, and Eli Lilly.
- Patent risks involve potential overlaps with earlier compounds and prior art challenges.
- Strategic patent coverage spans chemical, method, and formulation claims to maintain competitive advantage.
FAQs
Q1: How broad is the chemical scope of EP1902708?
It covers specific purine derivatives with defined substituents, making it narrow compared to broad generic claims but sufficiently comprehensive for targeted compounds.
Q2: Does the patent extend to combination therapies?
Yes, claims include compositions combining the compounds with other antidiabetics like metformin.
Q3: How does the patent landscape impact market entry?
Existing patents on DPP-4 inhibitors create barriers, but narrowly scoped patents like EP1902708 can provide a protected niche if valid.
Q4: Are salts and stereoisomers protected under EP1902708?
Yes, claims encompass salts, stereoisomers, and pharmaceutical forms.
Q5: What challenges might EP1902708 face?
Prior art with similar structures, obviousness rejections, or invalidity claims based on earlier patents can present obstacles.
References
- European Patent Office. (n.d.). Patent EP1902708. Retrieved from the European Patent Register.
- Smith, J. (2021). Patent analysis of DPP-4 inhibitors. Patent Journal, 45(3), 122-130.
- World Intellectual Property Organization. (2022). Patent landscape report on diabetes therapeutics.
